Alan Beresford

1.9k total citations
20 papers, 1.2k citations indexed

About

Alan Beresford is a scholar working on Pharmacology, Molecular Biology and Computational Theory and Mathematics. According to data from OpenAlex, Alan Beresford has authored 20 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 8 papers in Molecular Biology and 4 papers in Computational Theory and Mathematics. Recurrent topics in Alan Beresford's work include Pharmacogenetics and Drug Metabolism (11 papers), Analytical Chemistry and Chromatography (4 papers) and Computational Drug Discovery Methods (4 papers). Alan Beresford is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), Analytical Chemistry and Chromatography (4 papers) and Computational Drug Discovery Methods (4 papers). Alan Beresford collaborates with scholars based in United Kingdom, United States and Japan. Alan Beresford's co-authors include D. A. Stopher, P. V. Macrae, Michael H. Tarbit, Peter Eddershaw, Harold E. Selick, Martin K. Bayliss, Michael Humphrey, Brian Wood, Peter D. Howes and Darren V. S. Green and has published in prestigious journals such as Journal of Medicinal Chemistry, Drug Discovery Today and Toxicology.

In The Last Decade

Alan Beresford

20 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Beresford United Kingdom 12 348 333 277 250 217 20 1.2k
Chris Luscombe United Kingdom 10 511 1.5× 396 1.2× 115 0.4× 416 1.7× 117 0.5× 11 1.3k
Patrizia Crivori Italy 15 353 1.0× 674 2.0× 233 0.8× 670 2.7× 158 0.7× 27 1.6k
Yoshihiro Uesawa Japan 23 378 1.1× 610 1.8× 363 1.3× 326 1.3× 356 1.6× 167 1.8k
Mitchell N. Cayen China 21 112 0.3× 473 1.4× 349 1.3× 98 0.4× 239 1.1× 77 1.6k
John C. L. Erve United States 17 110 0.3× 371 1.1× 367 1.3× 116 0.5× 88 0.4× 26 1.0k
B. Michael Silber United States 21 185 0.5× 691 2.1× 650 2.3× 229 0.9× 374 1.7× 49 2.0k
Nathalie Chauret Canada 25 437 1.3× 607 1.8× 616 2.2× 151 0.6× 410 1.9× 64 1.9k
Fabio Broccatelli United States 18 301 0.9× 455 1.4× 328 1.2× 435 1.7× 123 0.6× 30 1.5k
Bernard Testa Switzerland 17 190 0.5× 326 1.0× 59 0.2× 125 0.5× 121 0.6× 21 861
Kamlesh P. Vyas United States 26 248 0.7× 606 1.8× 854 3.1× 211 0.8× 421 1.9× 58 2.3k

Countries citing papers authored by Alan Beresford

Since Specialization
Citations

This map shows the geographic impact of Alan Beresford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Beresford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Beresford more than expected).

Fields of papers citing papers by Alan Beresford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Beresford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Beresford. The network helps show where Alan Beresford may publish in the future.

Co-authorship network of co-authors of Alan Beresford

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Beresford. A scholar is included among the top collaborators of Alan Beresford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Beresford. Alan Beresford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beresford, Alan, Mark S. Chambers, Miki Nakanishi, et al.. (2020). Discovery of ONO-8590580: A novel, potent and selective GABAA α5 negative allosteric modulator for the treatment of cognitive disorders. Bioorganic & Medicinal Chemistry Letters. 30(22). 127536–127536. 1 indexed citations
2.
Shore, Daniel G., Zachary K. Sweeney, Alan Beresford, et al.. (2018). Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond – Part 2. Bioorganic & Medicinal Chemistry Letters. 29(4). 674–680. 8 indexed citations
3.
Beresford, Alan, et al.. (2006). Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery. Expert Opinion on Drug Metabolism & Toxicology. 2(2). 325–337. 51 indexed citations
4.
Tandon, Manish, et al.. (2004). The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorganic & Medicinal Chemistry Letters. 14(7). 1709–1712. 23 indexed citations
5.
Beresford, Alan, Matthew Segall, & Michael H. Tarbit. (2004). In silico prediction of ADME properties: are we making progress?. PubMed. 7(1). 36–42. 33 indexed citations
6.
Selick, Harold E., Alan Beresford, & Michael H. Tarbit. (2002). The emerging importance of predictive ADME simulation in drug discovery. Drug Discovery Today. 7(2). 109–116. 166 indexed citations
7.
Uings, Iain, Balasubramanian Palaniappan, Alan Beresford, et al.. (2001). MODIFIED PEPTIDE ANTAGONISTS OF INTERLEUKIN 5 EXHIBIT EXTENDED IN VIVO PERSISTENCE BUT RESTRICTED SPECIES SPECIFICITY. Cytokine. 15(1). 10–19. 4 indexed citations
8.
Eddershaw, Peter, Alan Beresford, & Martin K. Bayliss. (2000). ADME/PK as part of a rational approach to drug discovery. Drug Discovery Today. 5(9). 409–414. 155 indexed citations
9.
Lewis, D. F. V., Brian G. Lake, Stephen G. George, et al.. (1999). Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology. 139(1-2). 53–79. 49 indexed citations
10.
11.
Beresford, Alan, William J. Ellis, John Ayrton, M. A. Johnson, & David F. Lewis. (1997). Cytochrome P4501A(CYP1A) induction in rat and man by the benzodioxino derivative, fluparoxan. Xenobiotica. 27(2). 159–173. 5 indexed citations
12.
Beresford, Alan, et al.. (1996). Expression of human cytochrome P4501A1 (CYP1A1) in Saccharomyces cerevisiae inhibits cell division. Xenobiotica. 26(10). 1013–1023. 1 indexed citations
13.
Beresford, Alan, et al.. (1996). Expression of human cytochrome P4501A1 (CYP1A1) in Saccharomyces cerevisiae inhibits cell division. Xenobiotica. 26(1). 1013–1023. 1 indexed citations
14.
Beresford, Alan. (1993). CYP1A1: Friend or Foe?. Drug Metabolism Reviews. 25(4). 503–517. 51 indexed citations
15.
16.
Beresford, Alan, P. V. Macrae, & D. A. Stopher. (1988). Metabolism of amlodipine in the rat and the dog: A species difference. Xenobiotica. 18(2). 169–182. 30 indexed citations
17.
Beresford, Alan, et al.. (1988). Metabolism and kinetics of amlodipine in man. Xenobiotica. 18(2). 245–254. 68 indexed citations
18.
Stopher, D. A., Alan Beresford, P. V. Macrae, & Michael Humphrey. (1988). The Metabolism and Pharmacokinetics of Amlodipine in Humans and Animals. Journal of Cardiovascular Pharmacology. 12(Supplement 7). S55–S59. 139 indexed citations
19.
Beresford, Alan, P. V. Macrae, D. A. Stopher, & Brian Wood. (1987). Analysis of amlodipine in human plasma by gas chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 420(1). 178–183. 77 indexed citations
20.
Stopher, D. A., et al.. (1981). Isolation, characterization and direct estimation of dazoxiben and its glucuronide from human plasma and urine. Xenobiotica. 11(12). 849–856. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chris Luscombe Breakdown of academic impact, for papers by Patrizia Crivori Breakdown of academic impact, for papers by Yoshihiro Uesawa Breakdown of academic impact, for papers by Mitchell N. Cayen Breakdown of academic impact, for papers by John C. L. Erve Breakdown of academic impact, for papers by B. Michael Silber Breakdown of academic impact, for papers by Nathalie Chauret Breakdown of academic impact, for papers by Fabio Broccatelli Breakdown of academic impact, for papers by Bernard Testa Breakdown of academic impact, for papers by Kamlesh P. Vyas
Rankless by CCL
2026